A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →. With Quotient Sciences.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
76actual
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-29 | actual | When the study began enrolling |
| Primary completion | 2026-01-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-05 | actual | The whole study's end, after follow-up |
| First posted | 2023-11-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Overweight
Interventions
- Drug: GUB014295 — also filed as GUBamy
- Drug: GUB014295-PLACEBO
Primary outcomes
what the primary-completion date above is the date OFSafety - Adverse Events (AE) incidence
measured from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C
Safety - changes in vital signs
measured from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C
Safety - Safety laboratory parameters
measured From baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed